SEP 23, 2020 11:00 AM PDT

Meet the Expert

Speaker
  • Associate Professor of Cell and Developmental Biology, Vanderbilt University
    Biography

      Originally from the Midwest, Rebecca Ihrie completed undergraduate studies in biochemistry with honors at the University of Michigan, a PhD in cancer biology at Stanford University and a postdoctoral fellowship in the Alvarez-Buylla lab at the University of California, San Francisco. Her work has been recognized by Stanford's Lieberman award, the Damon Runyon Cancer Research Foundation, the American Association for Cancer Research/National Brain Tumor Society and an Ann Faulkenberry research grant from the Southeastern Brain Tumor Foundation.



      Since 2012, the Ihrie Lab at Vanderbilt University has studied the stem cells of the brain and stem-like cells in brain tumors using high-dimensional approaches. Using flow cytometry, her group revealed intrinsic differences in per-cell signaling capacity between groups of neural stem cells and showed that this difference is linked to the ability of these cells to form brain tumors. The laboratory also demonstrated that brain tumor contact with the brain stem cell niche is a key independent predictor of patient outcome.



      Recently the Ihrie Lab and collaborators used mass cytometry analysis of glioblastoma patient tissue and new machine learning algorithms to identify and deeply characterize novel, risk-stratifying populations of brain tumor cells.



      Ihrie is a founding member of Vanderbilt's Mass Cytometry Center of Excellence and a member of the Vanderbilt Brain Institute, the Vanderbilt Center for Stem Cell Biology and the Vanderbilt-Ingram Cancer Center. When not in the lab, she might be roller-skating skating with her family or outside in the garden.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    Loading Comments...
    Show Resources